Why the study?
Does pyrazinoylguanidine reduce hyperglycemia, hyperinsulinemia, and hyperlipidemia in patients with NIDDM and normal subjects receiving HCTZ?
Does pyrazinoylguanidine reduce hyperglycemia, hyperinsulinemia, and hyperlipidemia in patients with NIDDM and normal subjects receiving HCTZ?
Pyrazinoylguanidine demonstrates potential in reducing metabolic abnormalities and blood pressure in NIDDM patients and HCTZ-treated normal subjects.
Answers are grounded in this paper and cite their sources.
May mitigate HCTZ metabolic effects in NIDDM; hypothesis-generating, needs RCTs before practice consideration.
Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non-insulin-dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose-fatty acid cycle toward a more normal level in NIDDM patients and in non-diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients.
No takes yet. Share an insight, caveat, or question.
Vesell et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: